Venetoclax
Relapsed Adult AML
Medical College of WisconsinSmall moleculePhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 81/ 100
Competitive context
13 Active assets in the Relapsed Adult AML cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Azacitidine Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | B |
Cytosin-Arabinosid Medical College of Wisconsin | Phase 2 | B |
FILGRASTIM Medical College of Wisconsin | Phase 2 | B |
Omacetaxine The First Affiliated Hospital of Soochow University | Phase 2 | CCC |
Gilteritinib French Innovative Leukemia Organisation | Phase 2 | CCC |
View all 19 →
Same molecule, other indications
Venetoclax is also rated in:
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant
BBB
Indicative ·
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →